Travere Therapeutics, Inc. TVTX) on Wednesday reported a loss of $12.8 million in its second quarter. The San Diego-based ...

Q2 2025 Management View Eric M. Dube, President and CEO, described Q2 2025 as "a standout for Travere, a reflection of strong ...

Analysts are estimating that Travere Therapeutics will report an earnings per share (EPS) of $-0.12. The announcement from ...

Q2 2025 Earnings Call Transcript August 6, 2025 Travere Therapeutics, Inc. beats earnings expectations. Reported EPS is ...

Wedbush raised the firm’s price target on Travere Therapeutics (TVTX) to $32 from $30 and keeps an Outperform rating on the ...

Investing.com -- Travere Therapeutics, Inc. (NASDAQ: TVTX) reported stronger-than-expected second quarter 2025 financial results on Wednesday, driven by significant growth in FILSPARI sales, sending ...

Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.

Ligand Pharmaceuticals (NASDAQ:LGND), a biopharma company known for earning royalties from a broad portfolio of drugs, announced results for the second quarter of 2025 on August 7 ...

Institutional investors including Armistice Capital, RTW Investments, and Wellington Management have enlarged exposure to ...

Find the latest historical data for Travere Therapeutics, Inc. Common Stock (TVTX) at Nasdaq.com. View historical data in a monthly, bi-annual, or yearly format.

Vera Therapeutics' Phase 3 data on atacicept sparks optimism for IgAN treatment, but competition and market challenges may impact its potential.